NEW YORK, March 10, 2017 /PRNewswire/ --
Pre-market, Stock-Callers.com monitors the following equities: Surgical Care Affiliates Inc. (NASDAQ: SCAI), Nxstage Medical Inc. (NASDAQ: NXTM), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Sierra Oncology Inc. (NASDAQ: SRRA). These companies belong to the Healthcare sector, which outpaced most other sectors in the markets on Thursday, March 09th, 2017, with the NYSE Health Care Index rising almost 0.7%, while shares of health care companies in the S&P 500 were up 0.6% as a group. These stocks research reports can be downloaded now by simply registering for free at: http://stock-callers.com/registration Surgical Care Affiliates
Illinois headquartered Surgical Care Affiliates Inc.'s stock finished Thursday's session 0.09% lower at $56.65. A total volume of 908,206 shares was traded, which was above their three months average volume of 653,210 shares. Over the last month and the previous three months, the Company's shares have advanced 0.30% and 25.81%, respectively. Additionally, the stock has gained 22.43% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 3.40% and 18.63%, respectively. Moreover, shares of Surgical Care Affiliates, which together with its subsidiaries, owns and operates a network of multi-specialty ambulatory surgery centers and surgical hospitals primarily in the US, have a Relative Strength Index (RSI) of 49.48.
On February 21st, 2017, UnitedHealth Group Incorporated commenced an exchange offer for all of the outstanding shares of Surgical Care Affiliates (SCA), pursuant to the companies' previously announced merger agreement dated January 07th, 2017. Subject to the terms and conditions of the Offer, SCA' stockholders who validly tender their shares in the Offer will receive, for each share of SCA's common stock, cash and UnitedHealth Group's common stock valued at $57.00. The Offer is scheduled to expire at 12:01 a.m., ET on March 21st, 2017. Your complete research report on SCAI can be retrieved for free at: http://stock-callers.com/registration/?symbol=SCAI
Nxstage Medical
Shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. rose 1.68%, ending yesterday's session at $27.89 with a total trading volume of 250,358 shares. The stock has gained 0.40% in the past month, 12.55% in the previous three months, and 6.41% on an YTD basis. The Company's shares are trading 1.23% above their 50-day moving average and 14.93% above their 200-day moving average. Moreover, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 45.73.
On March 09th, 2017, NxStage Medical announced a series of new research results that highlight the potential for on-site hemodialysis with the NxStage® System One™ in skilled nursing facilities to significantly reduce Medicare costs, as well as demonstrate the clinical benefits of more frequent home hemodialysis. A free report on NXTM is just a click away at: http://stock-callers.com/registration/?symbol=NXTM
Esperion Therapeutics
On Thursday, Ann Arbor, Michigan headquartered Esperion Therapeutics Inc.'s stock saw a drop of 4.61%, to close the day at $32.45. A total volume of 2.22 million shares was traded, which was above their three months average volume of 694,530 shares. The Company's shares have surged 61.12% in the last one month, 177.83% in the previous three months, and 159.19% on an YTD basis. The stock is trading 81.22% and 135.13% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 73.92.
On February 28th, 2017, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On March 07th, 2017, Esperion Therapeutics announced the initiation of a Phase-2 clinical study (1002-038) to assess the efficacy and safety of triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin in patients with hypercholesterolemia. This non-registrational study will enable the Company to explore the potential market dynamics of these complementary oral LDL-C lowering therapies together. Sign up for your complimentary research report on ESPR at: http://stock-callers.com/registration/?symbol=ESPR
Sierra Oncology
Shares in Vancouver, Canada headquartered Sierra Oncology Inc. ended the day 0.70% higher at $1.43 with a total trading volume of 306,010 shares. The stock is trading below its 50-day moving average by 1.33%. Shares of the Company, which engages in developing DNA Damage Response therapeutics for the treatment of patients with cancer, have an RSI of 46.67.
On February 22nd, 2017, research firm Wedbush resumed its 'Outperform' rating on the Company's stock while revising its previous target price from $3 a share to $4 a share.
On March 02nd, 2017, Sierra Oncology announced that for the full year 2016 it incurred a net loss of $47.9 million compared to a net loss of $53.3 million for the full year 2015. At December 31st, 2016, Sierra Oncology had $109.0 million in cash and cash equivalents. Register for free on Stock-Callers.com and download the latest research report on SRRA at: http://stock-callers.com/registration/?symbol=SRRA
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
Pre-market, Stock-Callers.com monitors the following equities: Surgical Care Affiliates Inc. (NASDAQ: SCAI), Nxstage Medical Inc. (NASDAQ: NXTM), Esperion Therapeutics Inc. (NASDAQ: ESPR), and Sierra Oncology Inc. (NASDAQ: SRRA). These companies belong to the Healthcare sector, which outpaced most other sectors in the markets on Thursday, March 09th, 2017, with the NYSE Health Care Index rising almost 0.7%, while shares of health care companies in the S&P 500 were up 0.6% as a group. These stocks research reports can be downloaded now by simply registering for free at: http://stock-callers.com/registration Surgical Care Affiliates
Advertisement
Illinois headquartered Surgical Care Affiliates Inc.'s stock finished Thursday's session 0.09% lower at $56.65. A total volume of 908,206 shares was traded, which was above their three months average volume of 653,210 shares. Over the last month and the previous three months, the Company's shares have advanced 0.30% and 25.81%, respectively. Additionally, the stock has gained 22.43% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 3.40% and 18.63%, respectively. Moreover, shares of Surgical Care Affiliates, which together with its subsidiaries, owns and operates a network of multi-specialty ambulatory surgery centers and surgical hospitals primarily in the US, have a Relative Strength Index (RSI) of 49.48.
On February 21st, 2017, UnitedHealth Group Incorporated commenced an exchange offer for all of the outstanding shares of Surgical Care Affiliates (SCA), pursuant to the companies' previously announced merger agreement dated January 07th, 2017. Subject to the terms and conditions of the Offer, SCA' stockholders who validly tender their shares in the Offer will receive, for each share of SCA's common stock, cash and UnitedHealth Group's common stock valued at $57.00. The Offer is scheduled to expire at 12:01 a.m., ET on March 21st, 2017. Your complete research report on SCAI can be retrieved for free at: http://stock-callers.com/registration/?symbol=SCAI
Nxstage Medical
Shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. rose 1.68%, ending yesterday's session at $27.89 with a total trading volume of 250,358 shares. The stock has gained 0.40% in the past month, 12.55% in the previous three months, and 6.41% on an YTD basis. The Company's shares are trading 1.23% above their 50-day moving average and 14.93% above their 200-day moving average. Moreover, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 45.73.
On March 09th, 2017, NxStage Medical announced a series of new research results that highlight the potential for on-site hemodialysis with the NxStage® System One™ in skilled nursing facilities to significantly reduce Medicare costs, as well as demonstrate the clinical benefits of more frequent home hemodialysis. A free report on NXTM is just a click away at: http://stock-callers.com/registration/?symbol=NXTM
Esperion Therapeutics
On Thursday, Ann Arbor, Michigan headquartered Esperion Therapeutics Inc.'s stock saw a drop of 4.61%, to close the day at $32.45. A total volume of 2.22 million shares was traded, which was above their three months average volume of 694,530 shares. The Company's shares have surged 61.12% in the last one month, 177.83% in the previous three months, and 159.19% on an YTD basis. The stock is trading 81.22% and 135.13% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Esperion Therapeutics, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, have an RSI of 73.92.
On February 28th, 2017, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On March 07th, 2017, Esperion Therapeutics announced the initiation of a Phase-2 clinical study (1002-038) to assess the efficacy and safety of triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin in patients with hypercholesterolemia. This non-registrational study will enable the Company to explore the potential market dynamics of these complementary oral LDL-C lowering therapies together. Sign up for your complimentary research report on ESPR at: http://stock-callers.com/registration/?symbol=ESPR
Sierra Oncology
Shares in Vancouver, Canada headquartered Sierra Oncology Inc. ended the day 0.70% higher at $1.43 with a total trading volume of 306,010 shares. The stock is trading below its 50-day moving average by 1.33%. Shares of the Company, which engages in developing DNA Damage Response therapeutics for the treatment of patients with cancer, have an RSI of 46.67.
On February 22nd, 2017, research firm Wedbush resumed its 'Outperform' rating on the Company's stock while revising its previous target price from $3 a share to $4 a share.
On March 02nd, 2017, Sierra Oncology announced that for the full year 2016 it incurred a net loss of $47.9 million compared to a net loss of $53.3 million for the full year 2015. At December 31st, 2016, Sierra Oncology had $109.0 million in cash and cash equivalents. Register for free on Stock-Callers.com and download the latest research report on SRRA at: http://stock-callers.com/registration/?symbol=SRRA
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
